Develops next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), CAR T cell therapy, and TCR ...
Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Over two decades, Sangamo's scientists developed the most advanced, flexible and ...
Sigilon Therapeutics is developing improved treatments for chronic diseases using a novel type of therapeutic: implanted cells shielded by proprietary biomaterials from immune attack and the ...
